BLAINTRAVENOUSINJECTABLEPriority Review
Approved
Sep 2022
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
4/8 — Partial
Priority Review
SPEVIGO (spesolimab-sbzo) by Boehringer Ingelheim is interleukin-36 receptor antagonists [moa]. Approved for generalized pustular psoriasis. First approved in 2022.
Drug data last refreshed 18h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SPEVIGO (spesolimab-sbzo) is an intravenous interleukin-36 receptor antagonist approved by the FDA in September 2022 for generalized pustular psoriasis and under investigation for multiple inflammatory and autoimmune conditions. It blocks IL-36 signaling, a key driver of innate immune inflammation in rare and chronic inflammatory diseases. The drug targets patients with severe, treatment-resistant inflammatory conditions including hidradenitis suppurativa, ulcerative colitis, pyoderma gangrenosum, and atopic dermatitis.
$0.002BPart D
PeakEarly-stage product in peak phase with modest uptake (32 Part D claims in 2023) indicates a focused launch team supporting niche, high-severity patient populations.
Mechanism of Action
Interleukin-36 Receptor Antagonists
Pharmacologic Class:
Interleukin-36 Receptor Antagonist
Indications (1)
Career Relevance
SPEVIGO employment opportunities remain minimal in external job postings (0 linked roles), suggesting either early-stage team stability at Boehringer Ingelheim or reliance on contractor/agency staffing. The niche indication focus (GPP, HS) limits overall team size but creates specialized roles in medical affairs and patient services.
Worked on SPEVIGO at Boehringer Ingelheim? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.